These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

332 related items for PubMed ID: 10571998

  • 21. Reduction of 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, WIN 59075, SR 4233) to a DNA-damaging species: a direct role for NADPH:cytochrome P450 oxidoreductase.
    Fitzsimmons SA, Lewis AD, Riley RJ, Workman P.
    Carcinogenesis; 1994 Aug; 15(8):1503-10. PubMed ID: 8055626
    [Abstract] [Full Text] [Related]

  • 22. Adaptation of human tumor cells to tirapazamine under aerobic conditions: implications of increased antioxidant enzyme activity to mechanism of aerobic cytotoxicity.
    Elwell JH, Siim BG, Evans JW, Brown JM.
    Biochem Pharmacol; 1997 Jul 15; 54(2):249-57. PubMed ID: 9271329
    [Abstract] [Full Text] [Related]

  • 23. Molecular mechanisms for the hypoxia-dependent activation of 3-amino-1,2,4-benzotriazine-1,4-dioxide (SR 4233).
    Laderoute K, Wardman P, Rauth AM.
    Biochem Pharmacol; 1988 Apr 15; 37(8):1487-95. PubMed ID: 3128984
    [Abstract] [Full Text] [Related]

  • 24. Radical properties governing the hypoxia-selective cytotoxicity of antitumor 3-amino-1,2,4-benzotriazine 1,4-dioxides.
    Anderson RF, Shinde SS, Hay MP, Gamage SA, Denny WA.
    Org Biomol Chem; 2005 Jun 07; 3(11):2167-74. PubMed ID: 15917906
    [Abstract] [Full Text] [Related]

  • 25. Use of the comet assay to detect hypoxic cells in murine tumours and normal tissues exposed to bioreductive drugs.
    Olive PL.
    Acta Oncol; 1995 Jun 07; 34(3):301-5. PubMed ID: 7779413
    [Abstract] [Full Text] [Related]

  • 26. DNA damage measured by the comet assay in head and neck cancer patients treated with tirapazamine.
    Dorie MJ, Kovacs MS, Gabalski EC, Adam M, Le QT, Bloch DA, Pinto HA, Terris DJ, Brown JM.
    Neoplasia; 1999 Nov 07; 1(5):461-7. PubMed ID: 10933062
    [Abstract] [Full Text] [Related]

  • 27. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317.
    Siim BG, Pruijn FB, Sturman JR, Hogg A, Hay MP, Brown JM, Wilson WR.
    Cancer Res; 2004 Jan 15; 64(2):736-42. PubMed ID: 14744792
    [Abstract] [Full Text] [Related]

  • 28. A mass spectrometry study of tirapazamine and its metabolites. insights into the mechanism of metabolic transformations and the characterization of reaction intermediates.
    Zagorevskii D, Song M, Breneman C, Yuan Y, Fuchs T, Gates KS, Greenlief CM.
    J Am Soc Mass Spectrom; 2003 Aug 15; 14(8):881-92. PubMed ID: 12892912
    [Abstract] [Full Text] [Related]

  • 29. Tirapazamine is metabolized to its DNA-damaging radical by intranuclear enzymes.
    Evans JW, Yudoh K, Delahoussaye YM, Brown JM.
    Cancer Res; 1998 May 15; 58(10):2098-101. PubMed ID: 9605751
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Efficacy and site specificity of hydrogen abstraction from DNA 2-deoxyribose by carbonate radicals.
    Roginskaya M, Moore TJ, Ampadu-Boateng D, Razskazovskiy Y.
    Free Radic Res; 2015 May 15; 49(12):1431-7. PubMed ID: 26271311
    [Abstract] [Full Text] [Related]

  • 32. Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells.
    Evans JW, Chernikova SB, Kachnic LA, Banath JP, Sordet O, Delahoussaye YM, Treszezamsky A, Chon BH, Feng Z, Gu Y, Wilson WR, Pommier Y, Olive PL, Powell SN, Brown JM.
    Cancer Res; 2008 Jan 01; 68(1):257-65. PubMed ID: 18172318
    [Abstract] [Full Text] [Related]

  • 33. Modeling the action of an antitumor drug: a density functional theory study of the mechanism of tirapazamine.
    Ban F, Gauld JW, Boyd RJ.
    J Am Chem Soc; 2001 Aug 01; 123(30):7320-5. PubMed ID: 11472160
    [Abstract] [Full Text] [Related]

  • 34. Spin Trapping Hydroxyl and Aryl Radicals of One-Electron Reduced Anticancer Benzotriazine 1,4-Dioxides.
    Qi W, Yadav P, Hong CR, Stevenson RJ, Hay MP, Anderson RF.
    Molecules; 2022 Jan 26; 27(3):. PubMed ID: 35164077
    [Abstract] [Full Text] [Related]

  • 35. Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro.
    Siim BG, van Zijl PL, Brown JM.
    Br J Cancer; 1996 Apr 26; 73(8):952-60. PubMed ID: 8611431
    [Abstract] [Full Text] [Related]

  • 36. Photosensitization of guanine-specific DNA damage by a cyano-substituted quinoxaline di-N-oxide.
    Fuchs T, Gates KS, Hwang JT, Greenberg MM.
    Chem Res Toxicol; 1999 Dec 26; 12(12):1190-4. PubMed ID: 10604868
    [Abstract] [Full Text] [Related]

  • 37. Homologous recombination repair-dependent cytotoxicity of the benzotriazine di-N-oxide CEN-209: comparison with other hypoxia-activated prodrugs.
    Hunter FW, Wang J, Patel R, Hsu HL, Hickey AJ, Hay MP, Wilson WR.
    Biochem Pharmacol; 2012 Mar 01; 83(5):574-85. PubMed ID: 22182429
    [Abstract] [Full Text] [Related]

  • 38. Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine.
    Olive PL.
    Br J Cancer; 1995 Mar 01; 71(3):529-36. PubMed ID: 7880735
    [Abstract] [Full Text] [Related]

  • 39. Hypoxia-selective agents derived from quinoxaline 1,4-di-N-oxides.
    Monge A, Palop JA, López de Ceráin A, Senador V, Martínez-Crespo FJ, Sainz Y, Narro S, García E, de Miguel C, González M.
    J Med Chem; 1995 May 12; 38(10):1786-92. PubMed ID: 7752202
    [Abstract] [Full Text] [Related]

  • 40. SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.
    Brown JM.
    Br J Cancer; 1993 Jun 12; 67(6):1163-70. PubMed ID: 8512801
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.